CASE REPORT

Use of baclofen and propranolol for treatment of neurogenic fever in a patient with pontine hemorrhage: A case report

Saroj Poudel 💿 🛛	Rupak Chalise	Manoj Bist	Ashim Regmi	Anup Ghimire
Kishor Khanal				

Critical Care Medicine, Nepal Mediciti, Lalitpur, Nepal

Correspondence

Saroj Poudel, Critical Care Medicine, Nepal Mediciti, Lalitpur, Nepal. Email: itsmesarozz@gmail.com

Key Clinical Message

Neurogenic fever (NF) is a potentially life-threatening complication commonly seen in patients with pontine hemorrhage. This case report highlights the successful use of oral baclofen and propranolol as an effective treatment strategy to manage NF.

Abstract

Neurogenic fever (NF) is a common complication following pontine hemorrhage and poses significant challenges for clinicians in terms of diagnosis, management, and patient outcomes. This study delves into the efficacy of treatment methods involving baclofen and propranolol for neurogenic fever in patients with pontine hemorrhage. The results demonstrated a significant reduction in the duration and intensity of fever. Moreover, the treatment modality was well-tolerated and devoid of any adverse effects. These findings suggest that the use of oral baclofen and propranolol may be a promising therapeutic option for managing neurogenic fever in patients with pontine hemorrhage.

K E Y W O R D S

baclofen, central hyperpyrexia, neurogenic fever, pontine hemorrhage, propranolol

1 | INTRODUCTION

Hyperthermia is a prevalent occurrence, affecting nearly 70% of neuro-critically ill patients who are admitted with traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and intracerebral hemorrhage (ICH). Among these cases, half are attributed to noninfectious causes but are frequently misdiagnosed and managed as infectious fever, leading to unwarranted use of antibiotics, antimicrobial resistance, adverse drug reactions, increased treatment costs, and extended hospital stays.^{1,2}

The temperature elevation associated with neurogenic fever is notably high and often resistant to antipyretic medications, necessitating prompt and aggressive treatment to prevent secondary brain injury.³ In addition to external cooling methods, appropriate drug therapy is crucial. However, the lack of clinical practice guidelines for treating central hyperpyrexia leaves a knowledge gap.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2023 The Authors. *Clinical Case Reports* published by John Wiley & Sons Ltd.

WILEY-Clinical Case Reports

A multimodal approach involving propranolol, baclofen, amantadine, bromocriptine, and intravascular cooling has been recommended. This case report describes a successful treatment of severe traumatic brain injury with neurogenic fever using a combination of baclofen and propranolol.

2 | CASE PRESENTATION

A 27-year-old male arrived at the emergency department following a road traffic accident involving a collision with a four-wheeler while riding a bike. Initial medical attention was provided at a local hospital, where endotracheal intubation was performed due to a low Glasgow Coma Scale (GCS). Subsequently, he was referred to our center for advanced care.

Upon presentation, his vital signs were as follows: blood pressure 130/80 mmHg, heart rate 116 beats/min, temperature 38°C, and respiratory rate 24 breaths/min under controlled mechanical ventilation. His Spo2 was 97% on fio2 of 90%. The GCS score was 5 out of 15.

A magnetic resonance imaging (MRI) scan revealed diffuse axonal injury with pontine hemorrhage and subdural hematoma (Figure 1). He received conservative management to control intracranial pressure, prophylactic antibiotics, antiepileptic medication (levetiracetam), and other supportive treatments. Mean arterial pressure (MAP) was targeted to maintain cerebral perfusion pressure above 60 mmHg.

Laboratory results indicate leukocytosis with a total white cell count of 20,300 cells/cumm.

On the third day of ICU admission, the patient developed a continuous fever. Initial culture reports and a new set of laboratory tests (CBC, ESR, CRP, and procalcitonin) all returned negative for infections. A chest x-ray was performed to rule out ventilator-associated pneumonia, but no definitive cause for the fever could be identified.

Antipyretics and surface cooling measures were initiated, and empiric antibiotic therapy was upgraded to intravenous meropenem and polymyxin-B. Despite these efforts, the patient remained hyperpyretic (Figure 2). Due to difficulty in extubation, the patient was scheduled for tracheostomy.

On the seventh day of ICU admission, repeat cultures were taken, and procalcitonin levels remained low, yet the patient's clinical condition did not improve. Antimicrobials were further upgraded to intravenous tigecycline, and antifungal medication (caspofungin) was added. Echocardiography ruled out infective endocarditis, and a review of medications found no evidence of drug fever.

As neurogenic fever often presents with symptoms similar to infectious diseases, it took us almost 2 weeks to investigate and rule out various sources of infections one after another. After the fourteenth day of ICU admission, with all infectious causes excluded, antibiotics as well as antifungal were stopped and a diagnosis of central hyperpyrexia was established. Neuroleptic malignant syndrome too was excluded as other clinical features suggestive of the same were absent.

Following a thorough literature review, oral baclofen (10 mg Q8H) and propranolol (20 mg Q12H) were introduced. After 48 hours, the patient's temperature decreased to 38°C, occasionally spiking to 38.5–39°C. The doses of both medications were increased to: baclofen 20 mg Q8H and propranolol 20 mg Q8H.

After 10 days of treatment with baclofen and propranolol, the patient's temperature and heart rate returned to normal (Figure 3). Both medications were continued for an additional 4 days and then stopped, as the temperature and heart rate remained stable with no recurrence of fever. The patient was subsequently transferred to the ward.





FIGURE 1 (A and B) Plain MRI of the brain shows diffuse axonal injury with pontine hemorrhage.



/ILEY






FIGURE 3 Daily body temperatures of the patient after initiation of baclofen and propranolol.

3 | DISCUSSION

Neurogenic fever is a diagnosis of exclusion and remains a challenging condition to manage effectively. The traditional approach of supportive care and antipyretic medications often proves inadequate in controlling the underlying dysregulation of the autonomic nervous system. In this case report, we highlight the successful management of neurogenic fever using a combination of baclofen and propranolol.

NF is likely a result of direct pontine destruction or indirect compression. It is characterized by an unchanged setting of the thermoregulatory center so antipyretics have no effects on central hyperthermia.^{4,5} The combination of negative cultures; absence of infiltrate on chest radiographs; diagnosis of SAH, intraventricular hemorrhage, or tumor; and onset of fever within 72 hours of admission, predict NF with a probability of 0.90.⁶ Post-traumatic brain injury-related hyperthermia, also known as neurogenic fever is characterized by the development of hyperthermia, tachycardia, hyperhidrosis, hypertension, and sometimes seizures.⁷

Traumatic brain injury mechanisms include growth factor deficiency, which reduces sweating capacity and increases the risk of developing hyperthermia; direct injury to the hypothalamic–pituitary area and inflammatory changes within the hypothalamus; and diffuse white matter damage, which causes brain edema, hyper-glycemia, leukocytosis, hypotension, and seizure. All of these mechanisms result from autonomic dysfunction. This condition is also known as dysautonomia, paroxysmal sympathetic hyperactivity (PSH), or diencephalic syndrome.⁸

We hypothesized that baclofen would be effective in this case as it had an effect on central hyperthermia for patients with pontine hemorrhages. Baclofen, a GABA WILEY-Clinical Case Reports

agonist, functions as an inhibitory signal directly acting on the raphe nuclei to suppress BAT activation, which in turn suppresses the body temperatures. Thus, baclofen may control central hyperthermia by replacing neurotransmitters (GABA, glutamate) that were blocked due to the location of hemorrhage.⁹

We used baclofen at a dosage of 30 mg/day and titrated up to 60 mg/day, resulting in a complete resolution of fever. A study by Lee HC et al. also reports the efficacy of baclofen at a similar dosage to achieve normothermia in patients with central hyperthermia secondary to pontine hemorrhage. They started at a dose of 30 mg/day to a maximum of 60 mg/day with the reduction of fever from > $39-37.5^{\circ}$ C.¹⁰

Another study done by Huang YS et al successfully treated neurogenic fever with 30 mg/day of baclofen.⁸

Propranolol, a sympathetic blocking agent that can pass the blood-brain barrier can blunt the sympathetic storming phenomenon resulting in successful control of paroxysmal hyperthermia.¹¹ We expected that combining propranolol with baclofen would have a twofold effect of lowering his temperature as well as his heart rate in our patient, who also had sinus tachycardia with a heart rate ranging from 120 to 150.

Meythaler et al. published one of the earliest case reports of three cases of NF in severe TBI patients treated with propranolol.¹² Garg M et al. stated that propranolol 10 mg thrice daily was effective in alleviating fever and tachycardia for severe traumatic brain injury.¹³

The dosages mentioned in both studies were lower than the propranolol dose used in our study. In our patient, 60 mg/day of propranolol combined with 60 mg/day of baclofen provided adequate temperature and heart rate regulation. This dose of nonselective beta blocker has no negative effects.

4 | CONCLUSION

Our understanding of thermoregulatory failure in patients with brainstem hemorrhage has been enhanced by the current case. We should take prolonged central hyperthermia into account as a potential source of fever in cases of pontine strokes and take baclofen and propranolol into account as treatment options.

AUTHOR CONTRIBUTIONS

Saroj Poudel: Conceptualization; data curation; methodology; validation; visualization; writing – original draft; writing – review and editing. **Rupak Chalise:** Data curation; methodology; visualization; writing – original draft. **Manoj Bist:** Data curation; methodology; writing – review and editing. **Ashim Regmi:** Supervision; writing original draft; writing – review and editing. Anup
Ghimire: Supervision; writing – original draft; writing – review and editing. Kishor Khanal: Supervision; writing – original draft; writing – review and editing.

ACKNOWLEDGMENTS

We sincerely thank the patient and the members of our critical care department for their efforts.

FUNDING INFORMATION

None.

CONFLICT OF INTEREST STATEMENT

The authors have no conflict of interest to declare.

DATA AVAILABILITY STATEMENT

The data utilized in this case study primarily consist of patient medical records, clinical observations, and information obtained during routine clinical care. It can be accessed upon request from the corresponding author but is not publicly accessible due to privacy and ethical restrictions.

ETHICS STATEMEMT

This case report did not require the approval of any Ethical Committee. Written informed consent was obtained from the patient.

ORCID

Saroj Poudel D https://orcid.org/0000-0003-0879-176X

REFERENCES

- 1. Dimopoulos G, Falagas ME. Approach to the febrile patient in the ICU. *Infect Dis Clin North Am.* 2009;23:471-484.
- Kilpatrick MM, Lowry DW, Firlik AD, Yonas H, Marion DW. Hyperthermia in the neurosurgical intensive care unit. *Neurosurgery*. 2000;47:850-856.
- Reinert JP, Kormanyos Z. Pharmacologic Management of Central Fever: a review of evidence for bromocriptine, propranolol, and baclofen. *J Pharm Technol.* 2023;39(1):29-34. doi:10.1177/87551225221132678
- Boulant JA. Role of the preoptic-anterior hypothalamus in thermoregulation and fever. *Clin Infect Dis.* 2000;31:S157-S161.
- Zhao ZD, Yang WZ, Gao C, et al. A hypothalamic circuit that controls body temperature. *Proc Natl Acad Sci U S A*. 2017;114(8):2042-2047.
- Hocker SE, Tian L, Li G, Steckelberg JM, Mandrekar JN, Rabinstein AA. Indicators of central fever in the neurologic intensive care unit. *JAMA Neurol*. 2013;70:1499-1504.
- Thompson HJ, Tkacs NC, Saatman KE, Raghupathi R, McIntosh TK. Hyperthermia following traumatic brain injury: a critical evaluation. *Neurobiol Dis.* 2003;12:163-173.
- Thompson HJ, Hoover RC, Tkacs NC, Saatman KE, McIntosh TK. Development of posttraumatic hyperthermia after traumatic brain injury in rats is associated with increased

4 of 5

periven-tricular inflammation. *J Cereb Blood Flow Metab.* 2005;25:163-176.

- Huang YS, Hsiao MC, Lee M, Huang YC, Lee JD. Baclofen successfully abolished prolonged central hyperthermia in a patient with basilar artery occlusion. *Acta Neurol Taiwan*. 2009 Jun;18(2):118-122.
- Lee HC, Kim JM, Lim JK, Jo YS, Kim SK. Central hyperthermia treated with baclofen for patient with pontine hemorrhage. *Ann Rehabil Med.* 2014;38(2):269-272. doi:10.5535/ arm.2014.38.2.269
- 11. Ammar MA, Hussein NS. Using propranolol in traumatic brain injury to reduce sympathetic storm phenomenon: a prospective randomized clinical trial. *Saudi J Anaesth*. 2018;12(4):514-520. doi:10.4103/sja.SJA_33_18
- 12. Meythaler JM, Stinson AM. Fever of central origin in traumatic brain injury controlled with propranolol. *Arch Phys Med Rehabil.* 1994;75:816-818.

 Garg M, Garg K, Singh PK, et al. Neurogenic fever in severe traumatic brain injury treated with propranolol: a case report. *Neurol India*. 2019;67(4):1097-1099. doi:10.4103/002 8-3886.266258

How to cite this article: Poudel S, Chalise R, Bist M, Regmi A, Ghimire A, Khanal K. Use of baclofen and propranolol for treatment of neurogenic fever in a patient with pontine hemorrhage: A case report. *Clin Case Rep.* 2023;11:e7956. doi:10.1002/ccr3.7956